Compare VPG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | VNDA |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 474.0M |
| IPO Year | 2010 | 2005 |
| Metric | VPG | VNDA |
|---|---|---|
| Price | $44.78 | $6.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $53.50 | $14.90 |
| AVG Volume (30 Days) | 209.6K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $307,202,000.00 | $216,105,000.00 |
| Revenue This Year | $7.21 | $21.35 |
| Revenue Next Year | $6.92 | $37.40 |
| P/E Ratio | $111.93 | ★ N/A |
| Revenue Growth | 0.22 | ★ 8.72 |
| 52 Week Low | $18.57 | $3.81 |
| 52 Week High | $56.25 | $9.91 |
| Indicator | VPG | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 42.47 |
| Support Level | $44.01 | $4.39 |
| Resistance Level | $48.61 | $8.29 |
| Average True Range (ATR) | 2.64 | 0.44 |
| MACD | 0.36 | -0.14 |
| Stochastic Oscillator | 67.19 | 16.93 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.